



MAGNASENSE AND SALIGNOSTICS SUCCESSFULLY COMPLETE FEASIBILITY STUDY

Magnasense and Salignostics are pleased to announce the successful completion of their feasibility study, initiated in September 2024. The study evaluated the transfer of an existing Salignostics test onto Magnasense's platform. The results confirmed the compatibility of Salignostics' collection device with Magnasense's proprietary magnetic technology.

Marco Witteveen, CEO of Magnasense AB, stated:

"At Magnasense, we are committed to advancing diagnostic technology. Our collaboration with Salignostics has provided valuable insights into the potential of our magnetic test strip platform. We are encouraged by the study's results and look forward to further developments."

Dr. Guy Krief, Deputy CEO of Salignostics LTD, added:

"We are pleased with the study's outcome, which highlights the synergy between our sample collection expertise and Magnasense's magnetic technology. We look forward to exploring future opportunities together."

The data in this feasibility study is the property of Salignostics LTD.

For additional information, please contact:

Marco Witteveen, CEO, Magnasense AB

Email: ir@magnasense.com

The Company's Certified Adviser is Eminova Fondkommission AB | adviser@eminova.se

About Magnasense AB

Magnasense is a Swedish diagnostics company founded in 2019 to offer tests to monitor and optimize the dosage of biological drugs via its unique patented technology platform. In June 2020, Magnasense was listed on the Nasdaq First North Growth Market. The company's ambition is, in addition to bringing innovative diagnostic technology to the market, to make diagnostics more accessible, easier to use and to provide accurate and easily transferable results. For more information, see Magnasense's website www.magnasense.com.